544 related articles for article (PubMed ID: 35283347)
1. High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers.
Beck C; Allshouse A; Silver RM; Grobman WA; Simhan H; Haas D; Reddy UM; Blue NR
Am J Obstet Gynecol MFM; 2022 May; 4(3):100614. PubMed ID: 35283347
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis.
Chaemsaithong P; Gil MM; Chaiyasit N; Cuenca-Gomez D; Plasencia W; Rolle V; Poon LC
Am J Obstet Gynecol; 2023 Sep; 229(3):222-247. PubMed ID: 36990308
[TBL] [Abstract][Full Text] [Related]
3. Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes.
Coolman M; Timmermans S; de Groot CJ; Russcher H; Lindemans J; Hofman A; Geurts-Moespot AJ; Sweep FC; Jaddoe VV; Steegers EA
Obstet Gynecol; 2012 Jun; 119(6):1190-200. PubMed ID: 22617584
[TBL] [Abstract][Full Text] [Related]
4. Prediction of imminent preeclampsia at 35-37 weeks gestation.
Ciobanu A; Wright A; Panaitescu A; Syngelaki A; Wright D; Nicolaides KH
Am J Obstet Gynecol; 2019 Jun; 220(6):584.e1-584.e11. PubMed ID: 30738886
[TBL] [Abstract][Full Text] [Related]
5. Maternal serum levels of soluble fms-like tyrosine kinase-1 and placental growth factor at 20 and 28 weeks of gestational age and the risk of spontaneous preterm birth.
Sovio U; Gaccioli F; Cook E; Charnock-Jones DS; Smith GCS
Am J Obstet Gynecol; 2023 Aug; 229(2):164.e1-164.e18. PubMed ID: 36758709
[TBL] [Abstract][Full Text] [Related]
6. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
[TBL] [Abstract][Full Text] [Related]
7. Sequential plasma angiogenic factors levels in women with suspected preeclampsia.
Baltajian K; Bajracharya S; Salahuddin S; Berg AH; Geahchan C; Wenger JB; Thadhani R; Karumanchi SA; Rana S
Am J Obstet Gynecol; 2016 Jul; 215(1):89.e1-89.e10. PubMed ID: 26827880
[TBL] [Abstract][Full Text] [Related]
8. Early pregnancy angiogenic markers and spontaneous abortion: an Odense Child Cohort study.
Andersen LB; Dechend R; Karumanchi SA; Nielsen J; Joergensen JS; Jensen TK; Christesen HT
Am J Obstet Gynecol; 2016 Nov; 215(5):594.e1-594.e11. PubMed ID: 27287686
[TBL] [Abstract][Full Text] [Related]
9. Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV.
Conroy AL; McDonald CR; Gamble JL; Olwoch P; Natureeba P; Cohan D; Kamya MR; Havlir DV; Dorsey G; Kain KC
Am J Obstet Gynecol; 2017 Dec; 217(6):684.e1-684.e17. PubMed ID: 29031892
[TBL] [Abstract][Full Text] [Related]
10. The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).
Chaiworapongsa T; Romero R; Erez O; Tarca AL; Conde-Agudelo A; Chaemsaithong P; Kim CJ; Kim YM; Kim JS; Yoon BH; Hassan SS; Yeo L; Korzeniewski SJ
Am J Obstet Gynecol; 2017 Dec; 217(6):682.e1-682.e13. PubMed ID: 29037482
[TBL] [Abstract][Full Text] [Related]
11. The additive role of angiogenic markers for women with confirmed preeclampsia.
Suresh S; Patel E; Mueller A; Morgan J; Lewandowski WL; Verlohren S; von Dadelszen P; Magee LA; Rana S
Am J Obstet Gynecol; 2023 May; 228(5):573.e1-573.e11. PubMed ID: 36356699
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
[TBL] [Abstract][Full Text] [Related]
13. Placental protein levels in maternal serum are associated with adverse pregnancy outcomes in nulliparous patients.
Parry S; Carper BA; Grobman WA; Wapner RJ; Chung JH; Haas DM; Mercer B; Silver RM; Simhan HN; Saade GR; Reddy UM; Parker CB;
Am J Obstet Gynecol; 2022 Sep; 227(3):497.e1-497.e13. PubMed ID: 35487327
[TBL] [Abstract][Full Text] [Related]
14. Prenatal screening for preeclampsia: the roles of placental growth factor and pregnancy-associated plasma protein A in the first trimester and placental growth factor and soluble fms-like tyrosine kinase 1-placental growth factor ratio in the early second trimester.
Huang T; Rashid S; Priston M; Rasasakaram E; Mak-Tam E; Gibbons C; Mei-Dan E; Bedford HM
AJOG Glob Rep; 2023 May; 3(2):100193. PubMed ID: 37168546
[TBL] [Abstract][Full Text] [Related]
15. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
Holme AM; Roland MC; Henriksen T; Michelsen TM
Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
[TBL] [Abstract][Full Text] [Related]
16. Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood.
Chaiworapongsa T; Romero R; Gotsch F; Suksai M; Gallo DM; Jung E; Krieger A; Chaemsaithong P; Erez O; Tarca AL
Am J Obstet Gynecol; 2023 May; 228(5):569.e1-569.e24. PubMed ID: 36336082
[TBL] [Abstract][Full Text] [Related]
17. Circulating angiogenic factors and HIV among pregnant women in Zambia: a nested case-control study.
Smithmyer ME; Mabula-Bwalya CM; Mwape H; Chipili G; Spelke BM; Kasaro MP; De Paris K; Vwalika B; Sebastião YV; Stringer JSA; Price JT
BMC Pregnancy Childbirth; 2021 Jul; 21(1):534. PubMed ID: 34320947
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study.
Boutin A; Guerby P; Gasse C; Tapp S; Bujold E
Am J Obstet Gynecol; 2021 Feb; 224(2):204.e1-204.e7. PubMed ID: 32777265
[TBL] [Abstract][Full Text] [Related]
19. Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction.
Dathan-Stumpf A; Czarnowsky V; Hein V; Andraczek T; Stepan H
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1037-S1047.e2. PubMed ID: 33892922
[TBL] [Abstract][Full Text] [Related]
20. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction.
Arenas GA; Tang NY; Mueller A; Lopes Perdigao J; Kaur H; Abramowicz JS; Mussatt K; Yeo KJ; Rana S
Am J Obstet Gynecol MFM; 2021 Jul; 3(4):100394. PubMed ID: 33991706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
